ArticleBiological trace element research2026
Association Between Whole Blood Rubidium Levels and Anemia in Maintenance Hemodialysis Patients: A Multicenter Cross-Sectional Study.
Article in Biological trace element research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Anemia represents a common and clinically significant complication among maintenance hemodialysis (MHD) patients. Rubidium (Rb), which shares biochemical properties with potassium and enters cells through Na⁺/K⁺-ATPase, potentially influences erythrocyte function; however, its relationship with anemia in MHD populations has not been explored. This multicenter cross-sectional investigation enrolled 679 MHD patients from three hospitals in China during September to December 2021. Whole blood Rb concentrations were quantified using inductively coupled plasma mass spectrometry (ICP-MS). Anemia was defined as hemoglobin (Hb) below 11.0 g/dL. The association was evaluated through restricted cubic spline (RCS) analysis, multivariable logistic regression, and linear regression models. Anemia prevalence reached 55.23% in the study population. RCS analysis revealed an approximately linear inverse relationship between ln-transformed Rb and anemia risk (P for nonlinearity = 0.069, P overall < 0.001). Following adjustment for demographic factors, comorbidities, dialysis adequacy, nutritional markers, inflammatory indicators, iron metabolism parameters, and erythropoiesis-stimulating agent usage, each 1 mg/L elevation in Rb corresponded to 77% reduced odds of anemia (OR = 0.23, 95%CI: 0.11-0.39). Patients in the highest Rb quartile exhibited 70% lower anemia risk compared to those in the lowest quartile (OR = 0.30, 95%CI: 0.18-0.51; P for trend < 0.001). Each 1 mg/L Rb increment was associated with 1.471 g/dL higher Hb concentration (β = 1.471, 95%CI: 1.110-1.833). These associations persisted across all examined subgroups. Our findings indicate that elevated whole blood Rb levels independently correlate with reduced anemia prevalence and higher Hb concentrations in MHD patients, positioning Rb as a candidate biomarker for anemia risk stratification in this population.
Indexed as
Identifiers
42095957What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.